A Study of Ramucirumab (LY3009806) in Healthy Participants

Summary

This study evaluates a new formulation of ramucirumab, a drug approved for several types of cancer. In this study of healthy participants, a small amount of ramucirumab will be given by injection either into a vein or just under the skin. Study doctors will measure the amount of ramucirumab in the bloodstream. Side effects and tolerability will be documented. The study will last for about 16 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.

Timeline

Start

2020-07-30

Primary completion

2021-05-09

Completion

2021-05-09

Drugs

Indications

No indication recorded.